Bluebird Bio Selling 'An Overreaction,' Data Is 'Fantastic' Says Biotech Expert
- Shares of bluebird bio Inc (NASDAQ: BLUE) were trading down more than 20 percent on Thursday morning.
- The decline seems to have been triggered both by the company's earnings call and updated trial data for the treatment of beta-thalassemia.
- Noted biotech analyst Jason Napodano weighed in on the issue.
Bluebird bio on Thursday announced that two beta0-beta0 genotypes beta-thalassemia patients needed blood transfusions, while one remains transfusion dependent. Reacting to the news (also to the company’s financial results), the shares sold off in the morning hours.
Benzinga spoke with CFA Jason Napodano, who said, "the selling looks like an overreaction, as the data in non-B0/B0 patients looks fantastic and still like a cure.” Moreover, this represents two thirds of the market.
"The B0/B0 patients are 1/3rd of the market and still doing better than before," he added. "The SCD data looks fantastic."
Napodano continued, "if you thought the market opportunity for BLUE yesterday with Lenti was $X in BT and $Y in SCD, this morning it is 80% of $X (assume 100% of the 2/3rd non-B0/B0 + 50% of the 1/3rd B0/B0) + $Y."
To conclude, the expert assured there's "still a big market opportunity and with the stock down 60% off the highs," he believes the news is priced in. However, "the awe of a universal cure is gone, and that perception is hurting the stock."
Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.